HOPE-3 trial

Introduction

Study characteristics:

• 13,000 older adults without known cardiovascular disease with at least one risk factor*
• at baseline, mean LDL cholesterol level was 128 mg/dL, mean blood pressure was 138/82 mm Hg

* elevated waist-hip ratio, low HDL cholesterol, current smoking, or diet-controlled diabetes

Treatment groups:

• rosuvastatin 10 mg vs placebo, plus candesartan/HCTZ 16/12.5 mg vs placebo both QD

Outcomes:

• combined outcome of CV-related death, nonfatal stroke, or nonfatal myocardial infarction

Results: (~5.5 years' follow-up)

• rosuvastatin lowers mean LDL cholesterol level by 35 mg/dL, & reduces ombined outcome vs placebo (3.7 vs 4.8%)
  • rosuvastatin does NOT lower all-cause mortality
• candesartan/HCTZ reduced combined outcome vs placebo only in a subgroup with baseline systolic BP > 143 mm Hg (4.8 vs 6.5%)

More general terms

• clinical trial